Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma|Metastatic Nasopharyngeal Carcinoma|Chemotherapy Effect|Immunotherapy|Molecular Targeted Therapy
DRUG: Apatinib plus Camrelizumab
Objective response rate, Defined as the proportion of patients whose tumors shrink to complete response (CR) or partial response (PR) and remain for a certain period of time according to RECIST 1.1, 1 year
The proportion of patients who achieved disease control, Defined as the proportion of subjects who achieve CR+PR+stable disease (SD) for at least 4 weeks according to RECIST 1.1., 1 year|The proportion of patients who achieved clinical benefit, Defined as maintaining the efficacy of CR+PR+SD for at least 6 months according to RECIST 1.1., 1 year|median progression-free survival, Defined as the period from the start of enrollment until disease progression or death from any cause., 1 year|Duration of response, Defined as the time from the first assessment of CR and PR to the first assessment of PD or death caused by any cause according to RECIST 1.1., 1 year|Adverse events, NCI-CTC5.0 standard was adopted, and the safety was assessed mainly by clinical laboratory tests, ECOG-PS score, physical examination, electrocardiogram, and adverse event results., 1 year
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.